News and Announcements
H. Lee Moffitt Cancer Center Leukaemia Oncologist Joins SAB
- Published November 30, 2015 12:20PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
30th November 2015, ASX Announcement
Clinical stage oncology company Prescient Therapeutics Ltd (PTX) is delighted to announce the appointment of the H. Lee Moffitt Cancer Center’s Professor Jeffrey Lancet MD to PTX’s Scientific Advisory Board (SAB).
Professor Lancet is a medical oncologist whose work involves the development and implementation of clinical trials using small molecule inhibitors in acute leukemias.
This is of particular interest to PTX ahead of an upcoming clinical trial in Acute Myeloid Leukemia (AML) in early 2016.
Professor Lancet was an investigator on PTX’s earlier Phase 1 AML clinical trial conducted at MD Anderson and Moffitt Cancer Center in 32 patients with advanced haematologic malignancies.
To read the full announcement, please click here.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
